Cipla Q4 PAT rises 30% YoY to Rs 1,222 cr, revenue up 8%

Pharmaceutical major Cipla on Tuesday reported a 30% year-on-year (YoY) increase in net profit, reaching Rs 1,222 crore for Q4FY25, compared to Rs 939 crore in the same quarter last year. The net profit is attributable to the company's shareholders.

Additionally, revenue from operations rose 8.45% YoY to Rs 6,597.72 crore, up from Rs 6,082.37 crore in the corresponding quarter of the previous fiscal.

The company’s board of directors announced a total dividend of Rs 16 per share. This is inclusive of a final dividend of Rs 13 per share, along with a special dividend of Rs 3 per share.

The record date for the purpose of determining shareholder eligibility is June 27, and the same, if declared, will be paid to the entitled shareholders within 30 days from the date of the annual general meeting.

Further, the company’s EBITDA stood at Rs 1,537 crore for the March quarter of FY25, which also increased from Rs 1,316 crore, reported in the corresponding quarter of financial year 2025.

Segment-wise, for Q4FY25, Cipla’s pharmaceuticals segment reported a revenue of Rs 6,503.63 crore, compared to Rs 5,996.38 crore in Q4FY24. Meanwhile, the revenue from new ventures stood at Rs 288.48 crore in Q4FY25, up from Rs 212.99 crore in Q4FY24.

The Q4 results were announced during market hours. The stock was trading flat at Rs 1,519.30 on the BSE around 2:15 pm.